- Home
- PYPD vs ESLA Comparison
PYPD vs ESLA Comparison
Compare PYPD & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PYPD | ESLA |
|---|---|---|
| Founded | 2008 | 2021 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.1M | 69.5M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | PYPD | ESLA |
|---|---|---|
| Price | $4.68 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $12.25 | $8.00 |
| AVG Volume (30 Days) | ★ 158.8K | 29.9K |
| Earning Date | 05-06-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.06 | $0.78 |
| 52 Week High | $5.21 | $3.15 |
Technical Indicators
Market Signals| Indicator | PYPD | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 38.37 |
| Support Level | $4.60 | $1.00 |
| Resistance Level | $5.09 | $1.31 |
| Average True Range (ATR) | 0.31 | 0.11 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 30.86 | 15.95 |
Price Performance
Historical ComparisonAbout PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.